Cargando…

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Infante, Jeffrey R, Korn, Ronald L, Rosen, Lee S, LoRusso, Patricia, Dychter, Samuel S, Zhu, Joy, Maneval, Daniel C, Jiang, Ping, Shepard, H Michael, Frost, Gregory, Von Hoff, Daniel D, Borad, Mitesh J, Ramanathan, Ramesh K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785755/ https://www.ncbi.nlm.nih.gov/pubmed/29361630 http://dx.doi.org/10.1038/bjc.2017.438

Ejemplares similares

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
por: Infante, Jeffrey R, et al.
Publicado: (2018)

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
por: Printz, Marie A., et al.
Publicado: (2020)

ENHANZE(®) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
por: Locke, Kenneth W., et al.
Publicado: (2019)

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
por: Rosengren, Sanna, et al.
Publicado: (2015)

Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series
por: Jameson, Gayle S., et al.
Publicado: (2009)

(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
por: Korn, Ronald L., et al.
Publicado: (2017)

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models
por: Morosi, Lavinia, et al.
Publicado: (2021)

Modulation of Bleomycin-Induced Lung Fibrosis by Pegylated Hyaluronidase and Dopamine Receptor Antagonist in Mice
por: Skurikhin, Evgenii Germanovich, et al.
Publicado: (2015)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum]
Publicado: (2021)

Chondrocytes, synoviocytes and dermal fibroblasts all express PH-20, a hyaluronidase active at neutral pH
por: El Hajjaji, Hafida, et al.
Publicado: (2005)

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era [Corrigendum]
Publicado: (2015)

Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against Streptococcus pneumonia: both penicillin-sensitive and penicillin-resistant strains [Corrigendum]
Publicado: (2019)

Emodin-Conjugated PEGylation of Fe(3)O(4) Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]
Publicado: (2022)

Insights into the Antibacterial Mechanism of PEGylated Nano-Bacitracin A Against Streptococcus pneumonia: Both Penicillin-Sensitive and Penicillin-Resistant Strains [Corrigendum]
Publicado: (2022)

Hyaluronidase sensitivity: Our experience
por: Mayor, Rahul, et al.
Publicado: (2016)

A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration
por: Connor, Robert J., et al.
Publicado: (2020)

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer
por: Kang, David W., et al.
Publicado: (2021)

Corrigendum to: “A Novel Framework for Network-Targeted Neuropsychiatric Deep Brain Stimulation” by Anusha Allawala, BS, Kelly R Bijanki, PhD, Wayne Goodman, MD, Jeffrey F Cohn, PhD, Ashwin Viswanathan, MD, Daniel Yoshor, MD, David A Borton, PhD, Nader Pouratian, MD, PhD, Sameer A Sheth, MD, PhD. Neurosurgery, nyab112, https://doi.org/10.1093/neuros/nyab112
Publicado: (2021)

Corrigendum to: “Surgery for Degenerative Cervical Myelopathy: A Nationwide Registry-Based Observational Study With Patient-Reported Outcomes” by Sasha Gulati, MD, PhD, Vetle Vangen-Lønne, MS, Øystein P Nygaard, MD, PhD, Agnete M Gulati, MD, PhD, Tommy A Hammer, MD, Tonje O Johansen, MD, Wilco C Peul, MD, PhD, Øyvind O Salvesen, MSc, PhD, Tore K Solberg, MD, PhD. Neurosurgery, nyab259, https://doi.org/10.1093/neuros/nyab259
Publicado: (2021)

Active Expression of Human Hyaluronidase PH20 and Characterization of Its Hydrolysis Pattern
por: Pang, Bo, et al.
Publicado: (2022)

Toxicity of the recombinant human hyaluronidase ALT-BC4 on embryonic development
por: Lee, Ji Hye, et al.
Publicado: (2021)

Corrigendum to “Decreasing smoking during pregnancy: Potential economic benefit of reducing sudden unexpected infant death” [Preventive Medicine 140 (2020) 106238]
por: Higgins, Stephen T., et al.
Publicado: (2022)

Regulation of mitotic recombination between DNA repeats in centromeres
por: Zafar, Faria, et al.
Publicado: (2018)

Hyaluronidase: from clinical applications to molecular and cellular mechanisms
por: Buhren, Bettina Alexandra, et al.
Publicado: (2016)

jpHMM: improving the reliability of recombination prediction in HIV-1
por: Schultz, Anne-Kathrin, et al.
Publicado: (2010)

PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study
por: Seki, Tomohiro, et al.
Publicado: (2022)

Corrigendum to “Influence of the Thermal Treatment to Address a Better Osseointegration of Ti6Al4V Dental Implants: Histological and Histomorphometrical Study in a Rabbit Model”
por: Scarano, Antonio, et al.
Publicado: (2018)

The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials
por: Borad, Mitesh J., et al.
Publicado: (2012)

Hyaluronidase and pH Dual-Responsive Nanoparticles for Targeted Breast Cancer Stem Cells
por: Li, Weinan, et al.
Publicado: (2021)

Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
por: Pandit, Anuja, et al.
Publicado: (2021)

Identification of multiple genomic DNA sequences which form i-motif structures at neutral pH
por: Wright, Elisé P., et al.
Publicado: (2017)

Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy
por: Herraets, Ingrid J. T., et al.
Publicado: (2019)

THE INTERACTIONS OF THE NON-SPECIFIC INHIBITOR OF HYALURONIDASE WITH HYALURONIDASE AND PROTEOLYTIC ENZYMES IN VIVO
por: Hadidian, Z., et al.
Publicado: (1955)

pH-Responsive Artesunate Polymer Prodrugs with Enhanced Ablation Effect on Rodent Xenograft Colon Cancer [Corrigendum]
Publicado: (2020)

Corrigendum to “Cathepsin B pH-Dependent Activity Is Involved in Lysosomal Dysregulation in Atrophic Age-Related Macular Degeneration”
por: Voisin, Audrey, et al.
Publicado: (2020)

Hyaluronidases in Human Diseases
por: Kaul, Aditya, et al.
Publicado: (2021)

The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules [Corrigendum]
Publicado: (2018)

Preparation and biological evaluation of a novel pH-sensitive poly (β-malic acid) conjugate for antitumor drug delivery
por: Qiao, Youbei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hijvhtup6hsaakekk2qpa54d0o